Sunshine Biopharma Q3 2023 revenues surge to $5.96M on Nora Pharma acquisition; net loss narrows to $0.04/sh

Sunshine Biopharma Inc.

Gross revenues $5,957,668 for Q3 2023, up from $132,808 a year earlier, driven by Nora Pharma Inc. acquisition.
Net loss from operations narrowed to $651,482 ($0.04 per share) from $1,457,019 ($0.12 per share) in Q3 2022.
Sequential revenue growth: 7.1% from Q2 2023 ($5,560,865) and 21.7% from Q1 2023 ($4,894,053).
CEO Steve Slilaty stated focus on cost cutting and reaching profitability as key goals going forward.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Sunshine Biopharma Inc. reported the quarter ended September 30, 2023 results: revenue $5,957,668, net income net loss of $651,482 ($0.04 per share).

Period: the quarter ended September 30, 2023
Revenue: $5,957,668
Net income: net loss of $651,482 ($0.04 per share)
Result: reported results

Exact text from the filing

Sunshine Biopharma Inc. (NASDAQ: “SBFM”) (the “Company”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has filed its quarterly report for the 2023 third quarter. The Company reported gross revenues of $5,957,668 for the quarter ended September 30, 2023, an increase of $5,824,860 over the same period in 2022.

View on SEC.gov

Browse all earnings releases →

Sunshine Biopharma Inc. filing history →

Source: SEC EDGAR

accession 0001683168-23-007924

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.